Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives

(2022) Konstantinos Papamichael et al.   Lancet Gastroenterology & Hepatology

Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics

(2021) Richa Shukla et al.   Clinical Gastroenterology and Hepatology

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers

(2021) Guanglin Cui et al.   EBioMedicine

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

(2021) Adam S. Cheifetz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

(2020) David J. Gibson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

(2020) José Germán Sánchez‐Hernández et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

A nationwide survey on therapeutic drug monitoring of anti‐tumour necrosis factor agents for inflammatory bowel disease

(2020) Pepijn W.A. Thomas et al.   INTERNAL MEDICINE JOURNAL

Sa1023 AN INDIAN NATIONAL SURVEY OF THERAPEUTIC DRUG MONITORING WITH ANTI-TNF MEDICATIONS IN INFLAMMATORY BOWEL DISEASE

(2020) Gaurav B. Nigam et al.   GASTROENTEROLOGY

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

(2019) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

(2019) Samuel Raimundo Fernandes et al.   INFLAMMATORY BOWEL DISEASES

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

(2019) Nicholas A Kennedy et al.   Lancet Gastroenterology & Hepatology

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

(2019) Christopher Andrew Lamb et al.   GUT

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response

(2019) Miles P Sparrow et al.   Journal of Crohns & Colitis

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

(2019) Joana Torres et al.   Journal of Crohns & Colitis

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

(2018) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

(2018) Bram Verstockt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus

(2018) A Hillary Steinhart et al.   INFLAMMATORY BOWEL DISEASES

Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?

(2018) Mark A Samaan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

(2017) Niels Vande Casteele et al.   GASTROENTEROLOGY

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease

(2017) Laurie B Grossberg et al.   INFLAMMATORY BOWEL DISEASES

Crohn's disease

(2017) Joana Torres et al.   LANCET

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

(2016) Thomas Van Stappen et al.   Clinical and Translational Gastroenterology

Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

(2015) Mehmet Coskun et al.   CLINICAL PHARMACOKINETICS

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?

(2011) Ulf Hindorf et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

(2009) Klaus Bendtzen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY